Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
FMR LLC filed Amendment No. 3 reporting beneficial ownership of AVALO THERAPEUTICS INC common stock. As of June 30, 2026, FMR LLC and Abigail P. Johnson together reported beneficial ownership of 5,100,216 shares of common stock, representing 9.7% of the class. FMR LLC held 5,100,209 shares with sole voting power and 5,100,216 shares with sole dispositive power, with no shared voting or dispositive power reported. Abigail P. Johnson reported sole dispositive power over the same 5,100,216 shares, with no voting power. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.
Avalo Therapeutics, Inc. reported a net loss of $36.4 million for the quarter ended June 30, 2026 (six‑month net loss $56.0 million), driven by higher research and development spending as its IL‑1β programs advance. Quarterly basic and diluted net loss per share was $0.83 versus $1.92 a year earlier.
Research and development expenses rose to $23.4 million in the quarter and $37.5 million year‑to‑date, including a $10.0 million development milestone accrued to Eli Lilly for the planned phase 3 trial of abdakibart. A $6.6 million fair‑value charge related to the AlmataBio milestone buyout and changes in a $18.5 million derivative liability contributed to other expense.
The company reported positive Phase 2 LOTUS data in hidradenitis suppurativa, with abdakibart achieving HiSCR75 response rates of about 42% at both doses versus 25.6% for placebo and statistically significant secondary endpoints. Following these results, Avalo completed a follow‑on offering of common stock and pre‑funded warrants, generating net proceeds of $404.9 million. As of June 30, 2026, cash, cash equivalents and investments totaled $472.2 million, and management expects this to fund operations into 2029.
Avalo Therapeutics, Inc. reported second quarter 2026 results and business updates for its IL‑1β‑focused pipeline. The company plans to initiate a registrational Phase 3 program of abdakibart in hidradenitis suppurativa in the first half of 2027 and expects to submit an IND for its next‑generation anti‑IL‑1β antibody AVTX‑010 in the first half of 2027. It also appointed Ron Philip to the board and was added to the Russell 2000 and 3000 Indexes.
Cash, cash equivalents and investments totaled $472.2 million as of June 30, 2026 and are expected to fund operations into 2029. Net cash used in operating activities was $37.7 million for the first half of 2026. Second quarter 2026 research and development expenses were $23.4 million, up $9.3 million year over year, primarily due to a $10.0 million development milestone and other costs for abdakibart in HS. General and administrative expenses were $8.1 million, up $2.9 million, mainly from stock‑based compensation. Net loss was $36.4 million, an increase of $15.6 million year over year, with basic and diluted net loss per share of $0.83 versus $1.92 in the prior‑year quarter.
Avalo Therapeutics Chief Medical Officer Mittie Doyle exercised 1,000 stock options on July 27, 2026 at an exercise price of $12.65 per share, receiving 1,000 shares of common stock, then sold 1,000 shares at $20.00 per share the same day. After the exercise, Doyle holds 124,750 stock options at $12.65 expiring July 15, 2034. All transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025.
Avalo Therapeutics, Inc. filed a resale prospectus covering up to 128,189 shares of common stock, $0.001 par value, held by former AlmataBio stockholders under a Milestone Buyout Amendment Agreement. All shares may be sold from time to time by the selling stockholders; Avalo is not selling shares and will not receive proceeds from these resales.
Avalo is a clinical-stage biotechnology company focused on therapies targeting the interleukin-1β (IL-1β) pathway for immune-mediated inflammatory diseases. Lead antibody abdakibart (AVTX-009) met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa and is planned for advancement into a registrational Phase 3 program. As of July 10, 2026, there were 52,902,989 shares of common stock outstanding; AVTX trades on Nasdaq Capital Market, last reported at $19.50 per share on July 27, 2026.
BlackRock, Inc. reports a passive ownership stake in Avalo Therapeutics Inc common stock on a Schedule 13G. BlackRock and its reporting business units beneficially own 3,415,731 shares of Avalo common stock, representing 6.5% of the class. Of these, 3,371,733 shares carry sole voting power, and all 3,415,731 shares are subject to sole dispositive power, with no shared voting or dispositive authority. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single underlying interest exceeds five percent of Avalo’s outstanding common shares.
Avalo Therapeutics, Inc. has filed a resale registration covering up to 128,189 shares of common stock held by former AlmataBio, Inc. stockholders. These shares were issued under a Milestone Buyout Option Agreement and Amendment to the merger agreement with AlmataBio.
The registration enables the selling stockholders to sell their shares from time to time; Avalo is not selling any shares and will not receive proceeds from these resales, though it will bear registration expenses. The shares may be sold through various methods at prices based on the market price of Avalo’s Nasdaq‑listed stock (symbol AVTX; last reported price $17.88 per share on July 16, 2026).
Avalo is a clinical‑stage biotechnology company focused on IL‑1β‑targeted therapies. Its lead antibody, abdakibart (AVTX‑009), met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa, with 253 adults enrolled and statistically significant HiSCR75 responses at both doses. Based on these data, the company plans to advance abdakibart into a registrational Phase 3 program.
Avalo Therapeutics, Inc. receives a Schedule 13G/A amendment disclosing that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and shared dispositive power over 9,857 shares of Avalo common stock (CUSIP 05338F306). The filing lists shared voting and shared dispositive power of 9,857 and reports 0.0% of the class. The cover information is signed under a Joint Filing Agreement dated July 2, 2026.
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On June 30, 2026, Doyle sold 4,654 shares in an open-market sale at $20.00 per share, while also exercising options to acquire a total of 4,654 shares of common stock at strike prices of $8.04 and $12.65 per share. The options exercised relate to grants that vest over four years, and all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the trades were pre‑scheduled rather than discretionary market timing.